478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839)

• Inbal Barbiro,
• Amita Patnaik,
• Manish Sharma,
• Drew Rasco,
• Ryan Sullivan,
• Ecaterina Dumbrava,
• Pierre Ferre,
• Gini Fleming,
• Kyriakos Papadopoulos,
• Daniel Vaena,
• Adam ElNaggar,
• Adeboye Adewoye,
• Robina Smith,
• Emerson Lim

Affiliations

Inbal Barbiro

Aff1 grid.418916.30000 0004 0506 4804Compugen Ltd. Israel

Amita Patnaik

3South Texas Accelerated Research Therape, San Antonio, TX, USA

Manish Sharma

4 Department of Emergency Medicine, NewYork-Presbyterian Queens, Flushing, New York, USA

Drew Rasco

2The START Center for Cancer Care, San Antonio, TX, USA

Ryan Sullivan

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Ecaterina Dumbrava

1MD Anderson Cancer Center, Houston, TX, USA

Pierre Ferre

3Pierre Fabre Research Institute, Toulouse, France

Gini Fleming

3University of Chicago., Chicago, IL, USA

Kyriakos Papadopoulos

4START – San Antonio., San Antonio, TX, USA

Daniel Vaena

6West Cancer Center and Rsrch Institute., Memphis, TN, USA

Adam ElNaggar

6West Cancer Center and Rsrch Institute., Memphis, TN, USA

Adeboye Adewoye

7Compugen USA Inc., San Francisco, USA

Robina Smith

7Compugen USA Inc., San Francisco, USA

Emerson Lim

8Columbia University Cancer Center., New York City, NY, USA